In Brief: ChemTrak
This article was originally published in The Gray Sheet
ChemTrak: FDA requests more information regarding the firm's premarket approval application for the Aware home HIV test service. ChemTrak submitted the PMA in February 1995 ("The Gray Sheet" Feb. 20, 1995, In Brief). The company says it will respond to FDA's request "within the standard 180-day time frame set by the agency," noting that because of the "slower than previously anticipated development of the home HIV test market" it will focus more attention on "other opportunities which offer significantly greater short-term market potential"...
You may also be interested in...
Biopharma was an attractive investment in 2020 and fundamentals are unchanged in 2021, including the pandemic’s work-at-home requirements, which allowed more companies to go public faster.
Abbott reported almost 28% revenue growth in the fourth quarter led by the exploding demand for COVID-19 tests and continued success of its FreeStyle Libre continuous glucose monitor.
While representing a smaller population, the ACTIVATE-T trial targeted patients seen as having greater unmet need.